Allergan, Inc.
U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 1 (862) 261-7000
Website: http://www.allergan.com/
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
YEAR FOUNDED:
1948
LEADERSHIP:
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1188 articles about Allergan, Inc.
-
Polyphor to Enter into an Exclusive Agreement with Allergan Inc. for the Development of Protein Epitope Mimetics (PEM) Inhibitors for Ophthalmology; Allergan Entitled to Receive up to $61.0 Million
10/31/2008
-
Allergan Inc. Reports Third Quarter 2008 Operating Results
10/29/2008
-
Allergan Inc. And Spectrum Pharmaceuticals, Inc. Announce Collaboration Agreement for Apaziquone (EOquin(R)} for an Upfront Payment of $41.5M; Spectrum May Earn Up to $304 Million in Milestones and Retains Asian Rights
10/29/2008
-
BAROnova Secures Series B Financing of $7.5M From Allergan Inc.; New Obesity Intervention Device Moving to New Clinical Trials Has the Potential to be Safer and More Cost Effective Without Surgery
10/23/2008
-
Allergan Inc. Announces Quarterly Conference Call
10/6/2008
-
Allergan Inc. Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program; Studies Show Statistically Significant Decrease in Number of Headache Days; Stock Rises
9/11/2008
-
Asterand, Inc. to Enter Into Exclusive License Agreement with Allergan Inc. for Pre-Clinical Compounds Focused on Diseases of the Eye; Asterand to Receive Upfront Payment of $6.25M; Deal Could Produce of up to $56M in Milestone Payments, Plus Royalties
9/8/2008
-
Allergan Inc. Reports Second Quarter 2008 Operating Results
7/30/2008
-
Validity of Allergan Inc. Patents Acknowledged by Jan Marini in Settlement of Allergan Inc.'s Patent Infringement Suit Against Jan Marini Skin Research, Inc.
7/18/2008
-
QLT Inc. Completes Divestment of Aczone(R) to Allergan Inc. for USD$150 Million
7/14/2008
-
Allergan Inc. (JOBS) Failed to Warn of Dangerous Botox Side Effects, Lawsuit Claims
7/10/2008
-
Allergan Inc. Announces Quarterly Conference Call
7/9/2008
-
Allergan Inc. Receives U.S. FDA Approval for TRIVARIS(TM) (triamcinolone acetonide injectable suspension) 80 mg/mL
6/17/2008
-
QLT Inc. Announces Agreement to Sell Aczone(R) to Allergan Inc. for Approximately US$150 Million
6/10/2008
-
Allergan Inc. to Buy QLT Inc.'s Acne Gel for $150 Million
6/9/2008
-
Allergan Inc. Announces Intent to File New Drug Application for Bimatoprost as Novel Treatment to Stimulate Natural Eyelash Growth
6/4/2008
-
Indevus Pharmaceuticals, Inc. Licenses Canadian Rights for SANCTURA XR(TM) to Allergan Inc.; AllerganTo Pay Up To $9M To Each Of Indevus And Rottapharm Madaus
5/22/2008
-
Allergan Inc. Reports First Quarter 2008 Operating Results
5/7/2008
-
Galapagos NV and Allergan Inc. Enter Drug Discovery Collaboration
5/6/2008
-
Allergan Inc. Announces Research & Development Technology Review
5/2/2008